Esperion (NASDAQ: ESPR) (the Company) announces the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular and hepatic and renal disease. Through this acquisition, Esperion has acquired Corstasis, the developer and commercial sponsor of Enbumyst, the first and only FDA-approved nasal spray loop diuretic. Enbumyst received U.S. Food and Drug Administration (FDA) approval in September 2025 for the treatment of edema associated with congestive heart failure, as well as hepatic and renal disease in adults.
Read the full article: Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics //
Source: https://www.globenewswire.com/news-release/2026/04/02/3267808/0/en/Esperion-Therapeutics-Closes-Acquisition-of-Corstasis-Therapeutics-Expanding-Its-Cardiovascular-Franchise-with-Enbumyst-bumetanide-nasal-spray.html